Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Break Into The Boardroom Speaker Rallies Women At Annual Meeting To Play Nice

They came from far and near, all with similar purpose and ambition.

These women were a force to be reckoned with, including highly skilled strategic thinkers in the life science and healthcare sectors, from R&D to commercialization, operations, and regulatory affairs/compliance for both small and large cap companies.

Yet despite the high aptitude of this representative sample of female leaders, the stark reality is boards are only made up of 20% women.

The venue was the fourth annual meeting of Breaking into the Boardroom™ (BiB) held this past April. Deerfield, a co-founder, aims to change these statistics.

Speaker Jan Berger, MD, boiled the problem down to this when she addressed the crowd: “It used to be that the only diversity in the Boardroom was whether the male only members were sporting black, blue or grey socks.” Berger is president and chief executive officer of Health Intelligence Partners, a healthcare consultancy she founded.

The goal of BiB is to promote greater representation of female healthcare executives on boards within the public, private and non-profit sectors. Covering such topics as how to get a board seat, the role of governance, spectrum of board opportunities and legal and regulatory duties—the event lured 45 women from across the country, representing a broad cross section of experience from throughout the healthcare ecosystem.

Studies suggest that female-led companies are better run and bring greater returns[1], which begs the question why then are women still commercializing less and acquiring less venture capital when they do. On the upside, event speakers noted that men with daughters who have skin in the game tend to come around, suggesting their potential adaptability for change.

Among the reasons to account for the low number of female board members are a shrinking pool of candidates by the time the c-suite is reached with an upside down male to f